109 related articles for article (PubMed ID: 35965135)
1. Human sialoglycan ligands for immune inhibitory Siglecs.
Gonzalez-Gil A; Li TA; Kim J; Schnaar RL
Mol Aspects Med; 2023 Apr; 90():101110. PubMed ID: 35965135
[TBL] [Abstract][Full Text] [Related]
2. Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells.
Jia Y; Yu H; Fernandes SM; Wei Y; Gonzalez-Gil A; Motari MG; Vajn K; Stevens WW; Peters AT; Bochner BS; Kern RC; Schleimer RP; Schnaar RL
J Allergy Clin Immunol; 2015 Mar; 135(3):799-810.e7. PubMed ID: 25747723
[TBL] [Abstract][Full Text] [Related]
3. Gangliosides as Siglec ligands.
Schnaar RL
Glycoconj J; 2023 Apr; 40(2):159-167. PubMed ID: 36701102
[TBL] [Abstract][Full Text] [Related]
4. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?
Cao H; Crocker PR
Immunology; 2011 Jan; 132(1):18-26. PubMed ID: 21070233
[TBL] [Abstract][Full Text] [Related]
5. Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.
Läubli H; Varki A
Cell Mol Life Sci; 2020 Feb; 77(4):593-605. PubMed ID: 31485715
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
7. Advances in understanding and exploiting Siglec-glycan interactions.
Jame-Chenarboo Z; Gray TE; Macauley MS
Curr Opin Chem Biol; 2024 Jun; 80():102454. PubMed ID: 38631213
[TBL] [Abstract][Full Text] [Related]
8. Discovery, classification, evolution and diversity of Siglecs.
Angata T; Varki A
Mol Aspects Med; 2023 Apr; 90():101117. PubMed ID: 35989204
[TBL] [Abstract][Full Text] [Related]
9. Impact of Siglecs on autoimmune diseases.
Brzezicka KA; Paulson JC
Mol Aspects Med; 2023 Apr; 90():101140. PubMed ID: 36055802
[TBL] [Abstract][Full Text] [Related]
10. Probing the binding specificities of human Siglecs by cell-based glycan arrays.
Büll C; Nason R; Sun L; Van Coillie J; Madriz Sørensen D; Moons SJ; Yang Z; Arbitman S; Fernandes SM; Furukawa S; McBride R; Nycholat CM; Adema GJ; Paulson JC; Schnaar RL; Boltje TJ; Clausen H; Narimatsu Y
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33893239
[TBL] [Abstract][Full Text] [Related]
11. Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease.
Gonzalez-Gil A; Porell RN; Fernandes SM; Maenpaa E; Li TA; Li T; Wong PC; Aoki K; Tiemeyer M; Yu ZJ; Orsburn BC; Bumpus NN; Matthews RT; Schnaar RL
J Biol Chem; 2022 Jun; 298(6):101960. PubMed ID: 35452678
[TBL] [Abstract][Full Text] [Related]
12. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
13. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
Smith BAH; Deutzmann A; Correa KM; Delaveris CS; Dhanasekaran R; Dove CG; Sullivan DK; Wisnovsky S; Stark JC; Pluvinage JV; Swaminathan S; Riley NM; Rajan A; Majeti R; Felsher DW; Bertozzi CR
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215376120. PubMed ID: 36897988
[TBL] [Abstract][Full Text] [Related]
14. Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.
Ayyalasomayajula R; Cudic M
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611013
[TBL] [Abstract][Full Text] [Related]
15. Uncloaking the viral glycocalyx: How do viruses exploit glycoimmune checkpoints?
Domma AJ; Henderson LA; Nurdin JA; Kamil JP
Adv Virus Res; 2024; 119():63-110. PubMed ID: 38897709
[TBL] [Abstract][Full Text] [Related]
16. Siglecs in allergy and asthma.
Bochner BS; O'Sullivan JA; Chang AT; Youngblood BA
Mol Aspects Med; 2023 Apr; 90():101104. PubMed ID: 35835621
[TBL] [Abstract][Full Text] [Related]
17. Siglec-9 is an inhibitory receptor on human mast cells in vitro.
Miralda I; Samanas NB; Seo AJ; Foronda JS; Sachen J; Hui Y; Morrison SD; Oskeritzian CA; Piliponsky AM
J Allergy Clin Immunol; 2023 Sep; 152(3):711-724.e14. PubMed ID: 37100120
[TBL] [Abstract][Full Text] [Related]
18. Supplementing Glucose Intake Reverses the Inflammation Induced by a High-Fat Diet by Increasing the Expression of Siglec-E Ligands on Erythrocytes.
Liu H; Li J; Wu N; She Y; Luo Y; Huang Y; Quan H; Fu W; Li X; Zeng D; Jia Y
Inflammation; 2024 Apr; 47(2):609-625. PubMed ID: 38448631
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.
Angata T; Nycholat CM; Macauley MS
Trends Pharmacol Sci; 2015 Oct; 36(10):645-660. PubMed ID: 26435210
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases.
Wißfeld J; Abou Assale T; Cuevas-Rios G; Liao H; Neumann H
Front Neurol; 2024; 15():1330874. PubMed ID: 38529039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
